Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,739
  • Shares Outstanding, K 74,924
  • Annual Sales, $ 10,010 K
  • Annual Income, $ -15,730 K
  • 60-Month Beta 2.27
  • Price/Sales 5.34
  • Price/Cash Flow N/A
  • Price/Book 1.93
Trade RGLS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 947.90%
  • Historical Volatility 46.03%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 947.90% on 07/30/21
  • IV Low 80.80% on 09/18/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 413
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 20,324
  • Open Int (30-Day) 29,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +65.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6805 +3.44%
on 07/27/21
0.8350 -15.70%
on 07/01/21
-0.1092 (-13.43%)
since 06/30/21
3-Month
0.6805 +3.44%
on 07/27/21
1.4800 -52.44%
on 06/10/21
-0.6861 (-49.36%)
since 04/30/21
52-Week
0.4222 +66.72%
on 09/08/20
2.3200 -69.66%
on 03/12/21
-0.0558 (-7.35%)
since 07/30/20

Most Recent Stories

More News
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

/PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the presentation...

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

/PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it...

RGLS : 0.7039 (-1.35%)
Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced an incremental...

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that , President and...

RGLS : 0.7039 (-1.35%)
Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Regulus Therapeutics, Inc. (NASDAQ:RGLS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 5:00...

RGLS : 0.7039 (-1.35%)
Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that...

RGLS : 0.7039 (-1.35%)
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 0.7039 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

3rd Resistance Point 0.7454
2nd Resistance Point 0.7356
1st Resistance Point 0.7197
Last Price 0.7039
1st Support Level 0.6940
2nd Support Level 0.6842
3rd Support Level 0.6683

See More

52-Week High 2.3200
Fibonacci 61.8% 1.5950
Fibonacci 50% 1.3711
Fibonacci 38.2% 1.1472
Last Price 0.7039
52-Week Low 0.4222

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar